Petosemtamab Receives Breakthrough Therapy Designation From FDA
Petosemtamab Receives Breakthrough Therapy Designation From FDA
Petosemtamab 獲得 FDA 的突破性療法稱號
- Merus N.V. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-programmed cell death receptor-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) antibody.
- Merus N.V. 宣佈，美國食品藥品監督管理局（FDA）已授予petosemamab突破性療法稱號（BTD），用於治療複發性或轉移性頭頸部鱗狀細胞癌（HNSCC）患者，這些患者在鉑類化療和抗程序性細胞死亡受體-1（PD-1）或抗程序性死亡配體1（PD-L1）抗體治療後病情有所進展。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。